Benefit of Nasal Douche in COVID-19 Patients with Recurrence of Positive SARS-CoV-2 Viral RNA.
COVID-19
RT-PCR
nasal douche
re-positive
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2023
2023
Historique:
received:
08
06
2023
accepted:
07
09
2023
medline:
26
9
2023
pubmed:
26
9
2023
entrez:
26
9
2023
Statut:
epublish
Résumé
The purpose was to review relevant clinical data and formulate recommendations supporting the use of saline as a simple rinse for an early reassuring intervention to reduce the occurrence of re-positive COVID-19 patients. We conducted a single-centre retrospective cohort study, which enrolled patients with confirmed re-testing positive COVID-19 during 7-60 days after discharge from Third People's Hospital of Shenzhen. By one-to-two propensity score matching for age and sex, the control group of those not re-testing positive during the same period served as matched control. A total of 223 patients were included in our study, 94 in re-positive group and 129 in non-re-positive group. The result shows that the rates of nasal douche treatment in the non-re-positive group were considerably higher than that of the re-positive group. And the Ct value of nasal douche group increased faster than that of non-nasal douche group after the Ct value reaching ≥35. Further analysis revealed that the higher the Ct value at the time of readmission, the shorter the time of average Ct values to reach ≥35. These findings suggest that nasal douche is beneficial to shorten the time of virus nucleic acid turning negative, thereby reducing the incidence of re-positive. The prevention and control of epidemics focuses on re-positive patients with Ct values <35.
Identifiants
pubmed: 37750173
doi: 10.2147/IDR.S421380
pii: 421380
pmc: PMC10518237
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6269-6276Informations de copyright
© 2023 Liao et al.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose for this work.
Références
Int J Infect Dis. 2020 Apr;93:297-299
pubmed: 32147538
J Med Virol. 2020 Oct;92(10):1755-1756
pubmed: 32270882
Eur J Clin Microbiol Infect Dis. 2021 Jan;40(1):13-25
pubmed: 33113040
Int J Infect Dis. 2021 Oct;111:5-9
pubmed: 34391909
Glob Health Med. 2022 Dec 31;4(6):322-326
pubmed: 36589219
Eur J Clin Pharmacol. 2021 Sep;77(9):1275-1293
pubmed: 33772626
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
J Infect. 2020 Jul;81(1):147-178
pubmed: 32289343
Int J Immunopathol Pharmacol. 2020 Jan-Dec;34:2058738420941757
pubmed: 32799596
J Med Virol. 2020 Oct;92(10):2159-2164
pubmed: 32410245
JAMA Otolaryngol Head Neck Surg. 2021 Feb 1;147(2):218
pubmed: 33237269
Clin Infect Dis. 2020 Nov 19;71(16):2230-2232
pubmed: 32266381
Lancet. 2023 Mar 11;401(10379):833-842
pubmed: 36930674
Cochrane Database Syst Rev. 2020 Sep 16;9:CD013627
pubmed: 32936948
N Engl J Med. 2020 Mar 26;382(13):1278-1280
pubmed: 32069388
J Med Virol. 2020 Nov;92(11):2366-2367
pubmed: 32449789
JAMA Otolaryngol Head Neck Surg. 2020 Sep 1;146(9):787-788
pubmed: 32722777
N Engl J Med. 2020 Mar 5;382(10):970-971
pubmed: 32003551
J Med Virol. 2020 Jul;92(7):797-806
pubmed: 32198776